Bristol-Myers Squibb to Buy Amylin

NEW YORK ( TheStreet) -- Bristol-Myers Squibb ( BMY) announced late Friday that it's purchasing diabetes drugmaker Amylin Pharmaceuticals ( AMLN) in a deal valued at about $7 billion.

In a news release, the companies said Bristol-Myers will pay $31.00 a share in cash for San Diego-based Amylin.

That adds up to about $5.3 billion.

Including Amylin's net debt and a payment obligation to Eli Lilly & Co. ( LLY), however, the deal's total value rises to about $7 billion, the companies said.

The purchase price offers a 9.9% premium of to Amylin's closing share price Friday of $28.20.

The boards of Bristol-Myers and Amylin have approved the transaction.

In addition, following the consummation of the deal, New York-based Bristol-Myers plans expand its diabetes partnership with AstraZeneca PLC ( AZN). The companies will collaborate on developing and marketing Amylin's portfolio of drugs.

AstraZeneca will pay Bristol-Myers Squibb approximately $3.4 billion in cash, and the two partners will split profits and losses from the collaboration.

Shares of Bristol-Myers Squibb closed Friday up 87 cents at $35.95. Shares of AstraZeneca ended the session up 36 cents at $44.75.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact